Option Care Health (OPCH) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Net revenue for Q3 2024 was $1.28 billion, up 17% year-over-year, driven by organic growth in both acute and chronic therapies, with strong performance in rare and orphan portfolios.
Net income for Q3 2024 was $53.9 million, down 4.3% compared to Q3 2023, with a net margin of 4.2%.
Gross profit margin declined to 20.1% from 23.3% year-over-year, mainly due to higher cost therapies and less favorable procurement dynamics.
Operational recovery from the Change Healthcare incident is largely complete, with no material financial impact in Q3 2024, though patient payment collections remain delayed.
Navigated significant supply chain disruptions from Hurricane Helene, impacting IV solution availability and limiting new acute patient onboarding, with effects expected to continue into Q4.
Financial highlights
Revenue grew 17% year-over-year, with rare and orphan portfolios and established therapeutic categories as key drivers.
Gross profit dollars increased by $7.3 million sequentially from Q2; Q3 gross profit was $256.7 million.
Adjusted EBITDA reached $115.6 million, representing 9% of revenue and 5.3% growth over the prior year.
Cash flow from operations was $160.4 million for the quarter; cash balance stood at $483 million after $41.9 million in share repurchases.
For the nine months ended September 30, 2024, net income was $151.7 million on $3.65 billion revenue.
Outlook and guidance
Full-year 2024 revenue expected at $4.9–$4.95 billion; adjusted EBITDA guidance at $438–$443 million.
At least $300 million in cash flow from operations anticipated for 2024; effective tax rate projected at 26%-28%.
No 2024 impact from Stelara pricing changes; material gross profit impact expected in 2025, with further guidance to be provided in Q4 call.
Guidance reflects anticipated negative impact from ongoing supply chain disruption.
Medium- and long-term growth outlook remains high single-digit top-line and low double-digit enterprise growth.
Latest events from Option Care Health
- 2026 faces a $25M-$35M headwind amid strong growth, portfolio expansion, and operational investments.OPCH
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Strong growth, diversified revenue, and tech-driven expansion drive robust performance.OPCH
Investor presentation25 Feb 2026 - Q3 2025 revenue up 12.2%, adjusted EPS rose, net income fell, and guidance was raised.OPCH
Q3 202525 Feb 2026 - 2025 revenue up 13% to $5.65B; 2026 guidance signals further growth despite Stelara headwinds.OPCH
Q4 202524 Feb 2026 - Q3 2024 saw double-digit growth, margin expansion, and record-low leverage.OPCH
Bank of America Securities 2024 Leveraged Finance Conference3 Feb 2026 - Q2 revenue up 14.8%, net income down on tough comps, guidance and cash flow strong.OPCH
Q2 20242 Feb 2026 - Home infusion growth, innovation, and clinical expansion drive strong results and positive outlook.OPCH
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Double-digit revenue growth and expanded reach reinforce market leadership.OPCH
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Recovery and disciplined growth drive strong outlook, with M&A and innovation fueling future gains.OPCH
Jefferies Global Healthcare Conference31 Jan 2026